35834-26-5 Usage
Description
ROSAMICIN is a macrolide antibiotic that is effective against various bacterial strains, including Neissera gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, and Mycoplasma hominis. It functions by inhibiting bacterial protein synthesis, thereby treating and preventing infections caused by these pathogens.
Uses
Used in Pharmaceutical Industry:
ROSAMICIN is used as an antibiotic for treating and preventing infections caused by the aforementioned bacterial strains. Its effectiveness in combating these pathogens makes it a valuable asset in the fight against bacterial infections.
Used in Medical Research:
In addition to its direct application as an antibiotic, ROSAMICIN may also be used in medical research to study the mechanisms of antibiotic resistance and the development of new drugs to combat resistant strains. Its activity against specific bacteria can provide insights into the design of novel therapeutic agents.
Used in Diagnostics:
ROSAMICIN may also be utilized in diagnostic applications to identify and differentiate between various bacterial infections. Its specificity for certain bacterial strains can aid in the accurate diagnosis of infections, enabling targeted and effective treatment plans.
Biochem/physiol Actions
Macrolide antibiotic similar to erythromycin, and with a similar spectrum of bactericidal activity. Against a wide variety of anaerobes, rosamicin is at least as potent as, and in some cases more potent than, erythromycin.
Check Digit Verification of cas no
The CAS Registry Mumber 35834-26-5 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,5,8,3 and 4 respectively; the second part has 2 digits, 2 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 35834-26:
(7*3)+(6*5)+(5*8)+(4*3)+(3*4)+(2*2)+(1*6)=125
125 % 10 = 5
So 35834-26-5 is a valid CAS Registry Number.
InChI:InChI=1/C31H51NO9/c1-9-25-20(5)29-31(6,41-29)12-10-23(34)17(2)14-21(11-13-33)28(19(4)24(35)16-26(36)39-25)40-30-27(37)22(32(7)8)15-18(3)38-30/h10,12-13,17-22,24-25,27-30,35,37H,9,11,14-16H2,1-8H3/b12-10+/t17-,18-,19+,20?,21+,22+,24-,25?,27-,28-,29?,30+,31+/m1/s1
35834-26-5Relevant articles and documents
Chemoenzymatic Total Synthesis and Structural Diversification of Tylactone-Based Macrolide Antibiotics through Late-Stage Polyketide Assembly, Tailoring, and C-H Functionalization
Lowell, Andrew N.,Demars, Matthew D.,Slocum, Samuel T.,Yu, Fengan,Anand, Krithika,Chemler, Joseph A.,Korakavi, Nisha,Priessnitz, Jennifer K.,Park, Sung Ryeol,Koch, Aaron A.,Schultz, Pamela J.,Sherman, David H.
, p. 7913 - 7920 (2017/06/20)
Polyketide synthases (PKSs) represent a powerful catalytic platform capable of effecting multiple carbon-carbon bond forming reactions and oxidation state adjustments. We explored the functionality of two terminal PKS modules that produce the 16-membered tylosin macrocycle, using them as biocatalysts in the chemoenzymatic synthesis of tylactone and its subsequent elaboration to complete the first total synthesis of the juvenimicin, M-4365, and rosamicin classes of macrolide antibiotics via late-stage diversification. Synthetic chemistry was employed to generate the tylactone hexaketide chain elongation intermediate that was accepted by the juvenimicin (Juv) ketosynthase of the penultimate JuvEIV PKS module. The hexaketide is processed through two complete modules (JuvEIV and JuvEV) in vitro, which catalyze elongation and functionalization of two ketide units followed by cyclization of the resulting octaketide into tylactone. After macrolactonization, a combination of in vivo glycosylation, selective in vitro cytochrome P450-mediated oxidation, and chemical oxidation was used to complete the scalable construction of a series of macrolide natural products in as few as 15 linear steps (21 total) with an overall yield of 4.6%.
